Food Effect Studies for Oncology Drug Products-Reference-Cited by-同舟云学术

Food Effect Studies for Oncology Drug Products

Published:2017-03-20 Issue:5 Volume:101 Page:606-612
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Parsad S¹,Ratain MJ²

Affiliation:

1. University of Chicago Medicine; Chicago Illinois USA

2. University of Chicago; Chicago Illinois USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference5 articles.

1. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy;Singh;Clin. Pharmacokinet.,2004

2. Playing Russian roulette with tyrosine kinase inhibitors;Szmulewitz;Clin. Pharmacol. Ther.,2013

3. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm 2016

4. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours;Devriese;Invest. New Drugs,2014

5. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000ClinPharmR.pdf Vertex Pharmaceuticals. Telaprevir center for drug evaluation and research clinical pharmacology and biopharmaceutics review(s) 1 383 2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects;Investigational New Drugs;2023-12-15

2. The use of microtracers in food‐effect trials: An alternative study design for toxic drugs with long half‐lives exemplified by the case for alectinib;Clinical and Translational Science;2023-10-12

3. Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants;Clinical Pharmacology in Drug Development;2023-03-03

4. Evaluation of a Low‐Fat Low‐Calorie Meal on the Relative Bioavailability of Trametinib and Dabrafenib: Results From a Randomized, Open‐Label, 2‐Part Study in Healthy Participants;Clinical Pharmacology in Drug Development;2023-01-20

5. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?;Journal of Clinical Oncology;2021-11-01